Medigus Ltd. American Depositary Share - MDGS STOCK NEWS

Medigus Ltd. (Nasdaq: MDGS) announced a memorandum of understanding with Safee Cyber Technologies to enhance digital asset monetization. This partnership allows Eventer, Medigus' affiliate, to enable customers to create and sell NFTs via Safee’s platform. The collaboration aims to provide a recurring revenue model for creators while promoting NFT accessibility to a broader audience. As part of the agreement, both parties will exchange stakes based on their respective valuations of $30 million for Eventer and $35 million for Safee.

Medigus Ltd. (Nasdaq: MDGS) announced that its affiliate Gix Internet acquired 70% of Cortex Group for approximately $11 million, based on a pre-money valuation of $15.6 million. Cortex reported impressive financial growth, with revenues of about $13.5 million for H1 2021, a 53% increase year-over-year, and an operating profit of $1.3 million, up 121%. Q3 2021 also showed strong performance, with revenues of $12.5 million, a 92% increase. This acquisition is expected to significantly enhance Gix's financial results for 2021.

Medigus Ltd. (Nasdaq: MDGS) has announced a strategic investment of $400,000 in Safee, a Non-Fungible Token (NFT) technology firm. This investment will secure approximately 2.5% ownership in Safee. The company's platform aims to simplify NFT ownership for creators and consumers, fostering engagement and monetization in the digital marketplace. Medigus focuses on expanding NFT technology among mass-market audiences, enabling users to create, own, and trade digital assets securely. This collaboration aligns with Medigus’ innovative growth strategy in technology solutions.

Medigus Ltd. (Nasdaq: MDGS) has completed a corporate rebranding that includes a new logo, website, and investor lobby. This rebranding reflects the company's strategic goals to enhance its position as an innovative technology company. Medigus has reported record financial results for the first half of 2021, with revenues of $2,393,000 and a net income of $7,927,000. Shareholders’ equity reached $53,904,000, with cash and equivalents totaling $29,642,000 as of June 30, 2021.

Medigus Ltd. (Nasdaq: MDGS) announced a collaboration with iFulfillYou LLC to establish logistics warehouses in the U.S. through a new company, with Jeff Brands Ltd. holding 79% ownership. Jeff Brands will invest up to $3.5 million in the venture, aiming to enhance e-commerce support for sellers using Fulfillment By Merchant (FBM) on platforms like Amazon. The partnership will also develop proprietary A.I. software for inventory and logistics management, streamlining operations for online businesses in North America.

Medigus Ltd. (Nasdaq: MDGS) announced impressive financial results for the first half of 2021, reporting revenues of $2,393,000, marking a staggering 3,178% increase from $73,000 last year. The company achieved its first net profit of $7,927,000, reversing a net loss of $3,599,000 in H1 2020. As of June 30, 2021, shareholders’ equity stood at $53,904,000, with cash and cash equivalents at $29,642,000. Furthermore, Medigus is actively pursuing strategic technology acquisitions and has initiated a $2 million share buyback program.

Medigus Ltd. (Nasdaq: MDGS) announced that its joint venture Revoltz has commenced prototype manufacturing of the Model One micro-mobility vehicle in China.

This three-wheeled vehicle is designed for last-mile and food delivery, featuring a wide platform and two loading surfaces to carry more cargo than traditional scooters. The production aims to facilitate efficient urban deliveries while keeping costs low. The prototypes will help Revoltz refine its design and seek commercial partnerships.

Medigus Ltd. (Nasdaq: MDGS) announced that its partially-owned subsidiary, Polyrizon Ltd., is set to evaluate the prophylactic effects of its innovative product against the Delta variant of coronavirus. This follows pre-clinical studies showing effectiveness against human coronavirus 229E and influenza. The new study will commence in Q4 2021, focusing on preventing infections in conjunction with existing public health measures. Additionally, Polyrizon submitted a patent application for a novel hydrogel technology aimed at capturing biological threats.

Medigus Ltd. (Nasdaq: MDGS) announced that its affiliate, Polyrizon Ltd., submitted a new patent application for a hydrogel technology aimed at capturing biological intrusions in the upper airways. This pre-clinical study indicates that Polyrizon's product could potentially prevent infections from coronavirus and Influenza Virus H1N1. The technology aims to protect the nasal cavity and respiratory tract, possibly decreasing viral load and enhancing immune response.